AMGN Amgen, Inc.
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
Company profile
Ticker
AMGN
Exchange
Website
CEO
Robert A. Bradway
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
Gilead Sciences • Biogen • Qiagen • Bio-Techne • Moderna • Acorda Therapeutics • PDL BioPharma • BioNTech SE • bluebird bio • Denali Therapeutics ...
Former names
AMGEN
SEC CIK
Corporate docs
IRS number
953540776
Calendar
13 Feb 20
26 Feb 20
31 Dec 20
News
Company financial data Financial data
| Quarter (USD) | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|
| Revenue | 6.2B | 5.74B | 5.87B | 5.56B | |
| Net income | 1.7B | 1.97B | 2.18B | 1.99B | |
| Diluted EPS | 2.85 | 3.27 | 3.57 | 3.18 | |
| Net profit margin | 27.48% | 34.30% | 37.11% | 35.85% | |
| Operating income | 2.05B | 2.48B | 2.68B | 2.47B | |
| Net change in cash | 51M | -15M | -8M | 69M | |
| Cash on hand | 677M | 626M | 641M | 649M | |
| Cost of revenue | 1.25B | 1.04B | 1.01B | 1.06B |
| Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
|---|---|---|---|---|---|
| Revenue | 23.36B | 23.75B | 22.85B | 22.99B | |
| Net income | 7.84B | 8.39B | 1.98B | 7.72B | |
| Diluted EPS | 12.88 | 12.62 | 2.69 | 10.24 | |
| Net profit margin | 33.57% | 35.35% | 8.66% | 33.59% | |
| Operating income | 9.67B | 10.26B | 9.97B | 9.79B | |
| Net change in cash | 97M | 71M | 51M | 52M | |
| Cash on hand | 677M | 580M | 509M | 458M | |
| Cost of revenue | 4.36B | 4.1B | 4.07B | 4.16B |
Financial data from Amgen earnings reports
Institutional ownership Q4 2019
81.5% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 2015 |
| Opened positions | 275 |
| Closed positions | 109 |
| Increased positions | 650 |
| Reduced positions | 814 |
13F shares |
Current |
|---|---|
| Total value | 139.84B |
| Total shares | 480.71M |
| Total puts | 6.36M |
| Total calls | 5.54M |
| Total put/call ratio | 1.1 |
Largest owners |
Shares | Value |
|---|---|---|
| Vanguard | 48.47M | $11.69B |
| BLK BlackRock | 46.26M | $11.15B |
| Capital Research Global Investors | 35.34M | $8.52B |
| Wealth Quarterback | 31.16M | $31.16B |
| STT State Street | 26.23M | $6.32B |
| FMR | 24.49M | $5.9B |
| Primecap Management | 18.3M | $4.41B |
| Geode Capital Management | 10.03M | $2.41B |
| NTRS Northern Trust | 8.03M | $1.93B |
| BAC Bank of America | 7.54M | $1.82B |
Financial report summary
?Competition
Scios • Poniard Pharmaceuticals • Imclone Systems • Ir Biosciences • Celgene • ImmunoCellular Therapeutics • Novelion Therapeutics • Spectrum Pharmaceuticals • Allergan • MedimmuneManagement Discussion
- Future sales of our products will depend in part on the factors discussed in the Overview, Part I, Item 1. Business—Marketing, Distribution and Selected Marketed Products—Competition, in Part I, Item 1A. Risk Factors, and any additional factors discussed in the individual product sections below. In addition, for a list of our products’ significant competitors, see Part I, Item 1. Business—Marketing, Distribution and Selected Marketed Products—Competition.
- The increase in ENBREL sales for 2019 was driven primarily by favorable impacts from changes in accounting estimates of sales deductions and an increase in net selling price, offset partially by lower unit demand. For 2020, we expect the trend of lower unit demand to continue.
- The decrease in ENBREL sales for 2018 was driven primarily by lower unit demand and net selling price.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
AB, accuracy, ACME, advice, Alder, analytical, anniversary, Annora, anticompetitive, apremilast, atypical, autoinjector, AVSOLATM, backup, BAFF, Behcet, BeiGene, BioPharma, blocker, Blue, Brexit, bundled, buyer, CANDOR, Canyon, Castillo, celebrate, Celgene, Cesar, CGRP, chosen, Cleveland, cloud, cofounder, complement, comprised, conjugate, consortium, contemplate, contractile, contrast, convenience, costimulatory, Council, cured, curently, curiae, DARZALEX, deposit, disconnect, DOJ, door, downstream, DRL, eculizumab, ejection, embedded, eptinezumab, estate, evidentiary, exploring, EY, fast, formatted, fraction, Fraternal, gastric, GDPR, genital, Glenmark, griffith, hemoglobinuria, hemolytic, HFrEF, HHS, highest, HMO, homolog, immunogenicity, implicit, improperly, Indemnity, inflation, Inline, insufficient, insulin, interact, interactive, interval, intervenor, intervention, invention, Irrevocable, judgement, Kashiv, Kinney, Kirsten, KPH, lending, library, Lodge, lone, lookback, lymphocyte, lymphocytic, Maine, male, Mankind, Mayor, MDL, Miami, misrepresentation, MN, Momenta, MRD, MSP, multidistrict, mutation, myotrope, NaN, nearest, negligent, newest, nocturnal, NSCLC, nuclear, Nuevolution, obstructive, Officerand, oncogene, opposed, Orange, Otezla, otezla®, outage, overnight, overpaid, oversaw, overturned, overturning, panel, paroxysmal, path, payor, penalize, perspective, peter, petitioner, Pharmascience, phosphodiesterase, Pipe, platform, play, PNH, preemptive, preferential, preliminarily, prespecified, presumptively, Prinston, proceeding, prolonged, pulmonary, rat, real, refine, reply, rescheduled, restraining, revert, role, Rozibafusp, Run, Samsung, sarcoma, Scandinavian, sequencing, Sherwood, Shield, Shilpa, Slate, slated, sponte, St, stake, standing, stimulator, stressed, sua, sublease, successor, summer, SureClick, SwissBioSim, tableting, Tanvex, TDAPA, thicket, thrombocytopenia, thrombopoietin, UFCW, unanimously, unconstitutional, Unichem, unopposed, unrest, upholding, uremic, USPTO, vehicle, vendor, viral, waived, Wedbush, workforce
Removed:
ABB, accreted, Africa, African, aggregating, agile, attempting, automotive, Barr, BiTE, bortezomib, brand, Brazil, Cambridge, clarifying, compliant, composition, concluding, confronted, construct, coronary, darbepoetin, deadline, debated, declining, deliberately, disclosing, disposed, diversion, Donald, eligibility, ENDEAVOR, erythropoietin, ESPO, exchanged, excluding, exerting, frank, Friedrichshafen, fusion, gave, granting, herringer, improving, inclined, influence, infrastructure, insignificant, Insulet, integration, Lek, lengthen, lifecycle, lift, LUMICEF, Mexico, mid, monotherapy, North, occupy, older, Philadelphia, premium, preserving, prospectively, purifying, qualification, randomized, ranged, reallocate, recombinant, recommending, reinstated, reinvested, reliable, removing, renal, repealing, residential, ROMIPLATE, sBLA, separation, serving, sham, Sherman, sponsor, statute, subset, suspended, switching, TOWER, transformation, Trump, TRW, undistributed, vacated, variation, venture, vertically, withholding, Zealand, ZF
Financial reports
10-K/A
2019 FY
Annual report (amended)
13 Feb 20
10-K
2019 FY
Annual report
12 Feb 20
10-Q
2019 Q3
Quarterly report
30 Oct 19
10-Q
2019 Q2
Quarterly report
31 Jul 19
10-Q
2019 Q1
Quarterly report
1 May 19
10-K
2018 FY
Annual report
13 Feb 19
10-Q
2018 Q3
Quarterly report
31 Oct 18
10-Q
2018 Q2
Quarterly report
27 Jul 18
10-Q
2018 Q1
Quarterly report
25 Apr 18
10-K
2017 FY
Annual report
13 Feb 18
Current reports
8-K
Entry into a Material Definitive Agreement
21 Feb 20
8-K
Amgen Reports Fourth Quarter and Full Year 2019 Financial Results
30 Jan 20
8-K/A
Financial Statements and Exhibits
27 Jan 20
8-K
Regulation FD Disclosure
2 Jan 20
8-K
Entry into a Material Definitive Agreement
12 Dec 19
8-K
Completion of Acquisition or Disposition of Assets
21 Nov 19
8-K
Entry into a Material Definitive Agreement
31 Oct 19
8-K
Amgen Reports Third Quarter 2019 Financial Results
29 Oct 19
8-K
Departure of Directors or Certain Officers
23 Oct 19
8-K
Entry into a Material Definitive Agreement
18 Oct 19
Registration and prospectus
424B2
Prospectus for primary offering
20 Feb 20
FWP
Free writing prospectus
18 Feb 20
424B3
Prospectus supplement
18 Feb 20
S-3ASR
Automatic shelf registration
10 Feb 20
SC TO-I/A
Issuer tender offer statement (amended)
8 Mar 18
SC TO-I/A
Issuer tender offer statement (amended)
6 Mar 18
SC TO-I/A
Issuer tender offer statement (amended)
26 Feb 18
SC TO-I/A
Issuer tender offer statement (amended)
23 Feb 18
SC TO-I/A
Issuer tender offer statement (amended)
20 Feb 18
SC TO-I/A
Issuer tender offer statement (amended)
14 Feb 18
Proxies
DEFA14A
Additional proxy soliciting materials
13 May 19
DEFA14A
Additional proxy soliciting materials
2 May 19
DEFA14A
Additional proxy soliciting materials
29 Apr 19
DEFA14A
Additional proxy soliciting materials
22 Apr 19
DEFA14A
Additional proxy soliciting materials
8 Apr 19
DEF 14A
Definitive proxy
8 Apr 19
DEFA14A
Additional proxy soliciting materials
26 Apr 18
DEFA14A
Additional proxy soliciting materials
26 Apr 18
DEFA14A
Additional proxy soliciting materials
25 Apr 18
PX14A6G
Letter to shareholders
12 Apr 18
Other
CT ORDER
Confidential treatment order
24 Oct 19
CT ORDER
Confidential treatment order
3 Jun 19
CT ORDER
Confidential treatment order
30 May 18
CT ORDER
Confidential treatment order
17 May 18
CT ORDER
Confidential treatment order
4 Dec 17
CT ORDER
Confidential treatment order
8 Sep 17
CT ORDER
Confidential treatment order
15 Aug 17
CT ORDER
Confidential treatment order
26 May 17
CT ORDER
Confidential treatment order
8 May 17
CT ORDER
Confidential treatment order
6 Mar 17
Ownership
SC 13G/A
Beneficial ownership report (amended)
14 Feb 20
SC 13G/A
Beneficial ownership report (amended)
12 Feb 20
SC 13G
Beneficial ownership report
10 Feb 20
SC 13G/A
Kezar Life Sciences, Inc.
10 Feb 20
SC 13G/A
Amgen Inc
7 Feb 20
SC 13G/A
Amgen Inc
5 Feb 20
SC 13D
BeiGene, Ltd.
8 Jan 20
SC 13G
Provention Bio, Inc.
25 Sep 19
SC 13G/A
Amgen Inc
14 Feb 19
SC 13G/A
Amgen Inc
13 Feb 19
Patents
GRANT
Utility
Device and method for making aseptic connections
25 Feb 20
The present invention provides devices and methods for establishing aseptic connections between two or more components or subassemblies.
GRANT
Utility
Human antigen binding proteins that bind β-Klotho, FGF receptors and complexes thereof
25 Feb 20
The present invention provides compositions and methods relating to or derived from antigen binding proteins activate FGF21-mediated signaling.
APP
Utility
Kras G12C Inhibitors and Methods of Using the Same
20 Feb 20
Provided herein are methods of using KRAS G12C inhibitors and compositions of the same.
APP
Utility
Antibody Constructs for CLDN18.2 and CD3
20 Feb 20
The present invention relates to an antibody construct comprising a domain which binds to Claudin 18.2 (CLDN18.2) and another domain which binds to CD3.
GRANT
Utility
Interleukin-2 muteins for the expansion of T-regulatory cells
18 Feb 20
Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production.